Oxaprozin Potassium

Oxaprozin functions as a potent anti-inflammatory agent by directly inhibiting neutrophil migration towards chemotactic stimuli C5a and CXCL8, operating through mechanisms independent of cyclooxygenase inhibition. This pharmacological action involves the concentration-dependent suppression of key cellular activation events, including the upregulation of CD11b integrin expression, which is critical for leukocyte adhesion and transendothelial migration.
Furthermore, oxaprozin effectively blocks intracellular calcium flux and reactive oxygen species production induced by these G-protein coupled receptor ligands. By interfering with downstream signaling pathways, the drug prevents cytoskeletal rearrangements necessary for cell motility. This multi-target inhibition of early inflammatory responses limits the recruitment of immune cells to sites of tissue injury, providing a robust mechanistic basis for its therapeutic efficacy in chronic inflammatory conditions. The specific blockade of these GPCR-mediated signals highlights oxaprozin’s capacity to modulate immune cell function beyond traditional prostaglandin suppression, offering a distinct pharmacological profile that addresses the complex dynamics of neutrophil-driven inflammation.

Fig. 1 Treatment with Oxaprozin (Oxa) abrogates F-actin polymerization induced by C5a and CXCL8. (Bertolotto M.; et al. 2014)

Oxaprozin (OXP), a poorly water-soluble NSAID (BCS Class II), was used to form cocrystals with 4,4'-bipyridine and 1,2-bis(4-pyridyl)ethane, and molecular salts with piperazine, 2-amino-3-picoline, and the antiasthmatic drug salbutamol (SAL). All solids were characterized by DSC and X-ray diffraction. The OXP⁻-SAL⁺-H salt was of particular interest. While solubility/dissolution of OXP was only modestly affected by salt formation, the salt significantly reduced the solubility and intrinsic dissolution rate of SAL. In tablet dissolution tests, only 15% of SAL from the salt dissolved in 15 minutes compared to 89% of SAL base; 37% of the salt remained undissolved after 200 minutes. This drug-drug salt offers a potential extended-release formulation for SAL, addressing its short plasma half-life (2-3 hours) while providing synergistic anti-inflammatory effects from OXP for asthma treatment.

Fig. 2 Novel solid forms of Oxaprozin. (Aitipamula S.; et al. 2016)